Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 Sep;81(1):99-107.
doi: 10.1038/sj.bjc.6690657.

Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours

A H Thomson  1 , P A Vasey, L S Murray, J Cassidy, D Fraier, E Frigerio, C Twelves
Affiliations
Free PMC article
Clinical Trial

Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours

A H Thomson et al. Br J Cancer. 1999 Sep.
Free PMC article

Abstract

Doxorubicin pharmacokinetics were determined in 33 patients with solid tumours who received intravenous doses of 20-320 mg m(-2) HPMA copolymer bound doxorubicin (PK1) in a phase I study. Since assay constraints limited the data at lower doses, conventional analysis was not feasible and a 'population approach' was used. Bound concentrations were best described by a biexponential model and further analyses revealed a small influence of dose or weight on V1 but no identifiable effects of age, body surface area, renal or hepatic function. The final model was: clearance (Q) 0.194 I h(-1); central compartment volume (V1) 4.48 x (1+0.00074 x dose (mg)) I; peripheral compartment volume (V2) 7.94 I; intercompartmental clearance 0.685 I h(-1). Distribution and elimination half-lives had median estimates of 2.7 h and 49 h respectively. Free doxorubicin was present at most sampling times with concentrations around 1000 times lower than bound doxorubicin values. Data were best described using a biexponential model and the following parameters were estimated: apparent clearance 180 I h-(-1); apparent V1 (I) 1450 x (1+0.0013 x dose (mg)), apparent V2 (I) 21 300 x (1-0.0013 x dose (mg)) x (1+2.95 x height (m)) and apparent Q 6950 I h(-1). Distribution and elimination half-lives were 0.13 h and 85 h respectively.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Pharmacokinet Biopharm. 1977 Oct;5(5):445-79 - PubMed
    1. Cancer Res. 1986 Dec;46(12 Pt 1):6387-92 - PubMed
    1. Cancer Chemother Pharmacol. 1990;27(3):219-25 - PubMed
    1. Clin Pharmacol Ther. 1993 May;53(5):555-61 - PubMed
    1. J Clin Oncol. 1994 Jan;12(1):166-75 - PubMed

Publication types

MeSH terms

Substances